ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Semaglutide is on this study

  • No treatment in the record names it; a reading of the whole record found it given.
  • Claude Opus 5.5 judged it observed: patients on it are followed, not assigned it by the study. Nov 2, 2026, 12:35 AM UTC“Claims study of GLP-1 agonists and Alzheimer's”
  • The role rule had no answer: no treatment entry names it.
  • So Semaglutide's page lists this study under “Observed”.
8 links2 made here, not in the record6 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older versionMade here
Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT07677865GLP-1 Receptor Agonists andAlzheimer's Disease: AMulti-National Target TrialEmulationWest China HospitalwithdrawnRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 16 · ClinicalTrials.gov record · Version of 2026-10-16Version of 2026-10-16CONDITIONSAlzheimer DiseaseThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDiabetes Mellitus, Type 2The registry's MeSH filing›No judgment recorded. Shown as the registry files it.ObesityThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.OverweightThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.DRUGSGLP-1 receptor agonistsIntervention entry›Nov 18 · Rule based · ExposureExposureDPP-4 inhibitorsIntervention entry›Nov 18 · Rule based · ExposureExposureSemaglutideMade here · Found by reading; no entr…›Nov 1 · Claude Opus 5.5 · ExposureNov 2 · Claude Opus 5.5 · ExposureExposureTirzepatideMade here · Found by reading; no entr…›Nov 2 · Claude Opus 5.5 · ExposureExposure

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
1 version of the record seen on ClinicalTrials.gov, Oct 16 · changes seen, not judgments
Nov 1Semaglutidemade hereClaude Opus 5.5ExposureReplaced
Nov 2Semaglutidemade hereClaude Opus 5.5ExposureCurrent
Nov 2Tirzepatidemade hereClaude Opus 5.5ExposureCurrent
Nov 18GLP-1 receptor agonistsRule based · role ruleExposureCurrent
Nov 18DPP-4 inhibitorsRule based · role ruleExposureCurrent
As of nowAlzheimer DiseaseRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.